“On March 22, 2024, Grayscale Investments, LLC, the manager (the “Manager”) of Grayscale Digital Large Cap Fund LLC (the “Fund”) entered into Amendment No. 3 (“Amendment No. 3”) to the Fund’s Second Amended and Restated Limited Liability Company Agreement (the “LLC Agreement”) in order to modify the definition of “Business Day” (as defined therein).”
BTAIBioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein (collectively, the "Purchasers") valued at approximately $24.9 million (effective 2024-03-25).
“On March 25, 2024, BioXcel Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (collectively, the “Purchasers”).”
ETHEGrayscale Ethereum Staking ETF
Grayscale Ethereum Staking ETF amended Amendment No. 3 to the Amended and Restated Declaration of Trust and Trust Agreement with Delaware Trust Company valued at Modified the definition of Business Day from days when banks are closed to days when national securi (effective 2024-03-22).
“On March 22, 2024, Grayscale Investments, LLC, the sponsor (the “Sponsor”) of Grayscale Ethereum Trust (ETH) (the “Trust”) and the Delaware Trust Company, the trustee (the “Trustee”) of the Trust entered into Amendment No. 3 (the “Amendment No. 3”) to the Trust’s Amended and Restated Declaration of Trust and Trust Agreement (the “Trust Agreement”) in order to modify the definition of “Business Day” (as defined therein).”
ZCSHGrayscale Zcash Trust (ZEC)
Grayscale Zcash Trust (ZEC) amended Amendment No. 3 with Grayscale Investments, LLC and Delaware Trust Company (effective 2024-03-22).
“On March 22, 2024, Grayscale Investments, LLC, the sponsor (the “Sponsor”) of Grayscale Zcash Trust (ZEC) (the “Trust”) and the Delaware Trust Company, the trustee (the “Trustee”) of the Trust entered into Amendment No. 3 (the “Amendment No. 3”) to the Trust’s Amended and Restated Declaration of Trust and Trust Agreement (the “Trust Agreement”) in order to modify the definition of “Business Day” (as defined therein).”
CURO Group Holdings Corp.
CURO Group Holdings Corp. amended First Heritage Amendment with First Heritage Financing I, LLC (effective 2024-03-25).
“On March 25, 2024, First Heritage Financing I, LLC, an indirect wholly owned bankruptcy-remote subsidiary of the Company, entered into an amendment (the " First Heritage Amendment ") to its asset-backed warehouse facility (the " First Heritage Warehouse ") with the Class A lenders and agents party thereto and Class B lenders and agents party thereto, First Heritage Credit, LLC, a wholly-owned subsidiary of the Company, as servicer, certain other wholly-owned subsidiaries of the Company, as originators and subservicers, and certain other parties thereto.”
CURO Group Holdings Corp.
CURO Group Holdings Corp. entered into Restructuring Support Agreement with Consenting Stakeholders (effective 2024-03-22).
“On March 22, 2024, CURO Group Holdings Corp. (the " Company ") and certain of its direct and indirect subsidiaries (together with the Company, the " Company Parties ") entered into a Restructuring Support Agreement (together with all exhibits and schedules thereto, the " RSA ") with (i) certain lenders under the First Lien Credit Agreement, dated as of May 15, 2023”
ETCGGrayscale Ethereum Classic Trust (ETC)
Grayscale Ethereum Classic Trust (ETC) amended Amendment No. 4 to Second Amended and Restated Declaration of Trust and Trust Agreement with Grayscale Investments, LLC and Delaware Trust Company (effective 2024-03-22).
“On March 22, 2024, Grayscale Investments, LLC, the sponsor (the “Sponsor”) of Grayscale Ethereum Classic Trust (ETC) (the “Trust”) and the Delaware Trust Company, the trustee (the “Trustee”) of the Trust entered into Amendment No. 4 (the “Amendment No. 4”) to the Trust’s Second Amended and Restated Declaration of Trust and Trust Agreement (the “Trust Agreement”) in order to modify the definition of “Business Day””
flooidCX Corp.
flooidCX Corp. terminated Agreement and Plan of Merger with Quantum Energy, Inc. valued at Termination of the merger agreement released parties from all liabilities (effective 2024-03-21).
“the parties entered into a termination agreement which officially terminated the merger and the merger agreement, and released the parties from all liabilities related thereto.”
MTDRMatador Resources Co
Matador Resources Co entered into Fifth Amendment to Fourth Amended and Restated Credit Agreement with MRC Energy Company valued at $2.50 billion borrowing base, $3.50 billion maximum facility amount, $1.50 billion elected borrowing (effective 2024-03-22).
“On March 22, 2024, MRC Energy Company, a wholly owned subsidiary of Matador Resources Company (the “Company”), entered into a Fifth Amendment to Fourth Amended and Restated Credit Agreement (the “Amendment”), which amends the Company’s secured revolving credit facility (the “Credit Agreement”) to, among other things, (i) reaffirm the borrowing base at $2.50 billion, (ii) increase the maximum facility amount from $2.0 billion to $3.50 billion, (iii) increase the elected borrowing commitments from $1.325 billion to $1.50 billion, (iv) extend the maturity date from October 2026 to March 2029 and (v) replace Truist Bank with PNC Bank, National Association as administrative agent thereunder.”
VIVKVivakor, Inc.
Vivakor, Inc. entered into Membership Interest Purchase Agreement with Jorgan Development, LLC and JBAH Holdings, LLC valued at $120 million (effective 2024-03-21).
“Vivakor, Inc., (the “Company” or “Purchaser”) entered into a Membership Interest Purchase Agreement, a copy of which is filed herewith as Exhibit 2.1 (the “MIPA”) and incorporated by reference herein, with Jorgan Development, LLC, a Louisiana limited liability company (“Jorgan”) and JBAH Holdings, LLC, a Texas limited liability company (“JBAH” and, together with Jorgan, the “Sellers”)”
Evoke Pharma Inc
Evoke Pharma Inc amended Warrant Amendment with certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants (effective 2024-03-25).
“On March 25, 2024, Evoke Pharma, Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders (each, a “Holder”) of its outstanding Series A Warrants to purchase shares of common stock (the “Series A Warrants”), Series B Warrants to purchase shares of common stock (the “Series B Warrants”), and Series C Warrants to purchase shares of common stock (the “Series C Warrants”).”
UUUUENERGY FUELS INC
ENERGY FUELS INC terminated Controlled Equity Offering SM Agreement dated May 6, 2019 with Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC, and Roth Capital Partners, LLC (effective 2024-03-22).
“Effective March 22, 2024, the Controlled Equity Offering SM Agreement dated May 6, 2019 by and among the Company, Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC, and Roth Capital Partners, LLC (the "2019 Sales Agreement") was mutually terminated.”
UUUUENERGY FUELS INC
ENERGY FUELS INC entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., BMO Capital Markets Corp., Canaccord Genuity LLC, B. Riley Securities Inc. (effective 2024-03-22).
“On March 22, 2024, Energy Fuels Inc. (the "Company") entered into a Controlled Equity Offering SM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"), BMO Capital Markets Corp. ("BMO" and together with Cantor, the "Lead Agents" and individually "Lead Agent"), Canaccord Genuity LLC and B. Riley Securities Inc.”
DUOTDUOS TECHNOLOGIES GROUP, INC.
DUOS TECHNOLOGIES GROUP, INC. entered into Series E Purchase Agreement with certain accredited investors valued at proceeds of $2,125,002 (effective 2024-03-22).
“Pursuant to the other agreement (the "Series E Purchase Agreement" and, collectively with the Series D Purchase Agreement, the “Purchase Agreements”), the Company issued an aggregate of 2,125 shares of Series E Convertible Preferred Stock (the “Series E Preferred Stock”) and the Company received proceeds of $2,125,002.”
DUOTDUOS TECHNOLOGIES GROUP, INC.
DUOS TECHNOLOGIES GROUP, INC. entered into Series D Purchase Agreement with certain accredited investors valued at proceeds of $500,000 (effective 2024-03-22).
“Pursuant to one agreement (the “Series D Purchase Agreement”), the Company issued an aggregate of 500 shares of Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and the Company received proceeds of $500,000.”
CCOClear Channel Outdoor Holdings, Inc.
Clear Channel Outdoor Holdings, Inc. entered into CCIBV Credit Agreement with JPMorgan Chase Bank, N.A. valued at $375.0 million (effective 2024-03-22).
“On March 22, 2024 (the “Closing Date”), Clear Channel International B.V., a Dutch private company with limited liability (“CCIBV”), an indirect, wholly owned subsidiary of Clear Channel Outdoor Holdings, Inc. (the “Company”) entered into a credit agreement (the “CCIBV Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (in such capacities, the “Agent”), and J.P. Morgan SE, as lead arranger and bookrunner.”
DRTTFDIRTT ENVIRONMENTAL SOLUTIONS LTD
DIRTT ENVIRONMENTAL SOLUTIONS LTD entered into Support and Standstill Agreement with 22NW Fund, LP valued at Aron English to be nominated as director; 22NW agrees to vote in favor of Board recommendations and (effective 2024-03-22).
“On March 22, 2024, the Board approved (with one Board member dissenting), and the Company entered into, the Definitive Agreement.”
IntelGenx Technologies Corp.
IntelGenx Technologies Corp. amended Third Amended and Restated Loan Agreement with ATAI Life Sciences AG (effective 2024-03-11).
“IntelGenx Technologies Corp. (the " Corporation ") entered into a Third Amended and Restated Loan Agreement dated March 11, 2024 (the " Loan Agreement ") with its wholly-owned subsidiary, IntelGenx Corp., and ATAI Life Sciences AG (" atai "), which amends and restates the Second Amended and Restated Loan Agreement”
XEROX CORP
XEROX CORP entered into a notes offering valued at $500 million aggregate principal amount (effective 2024-03-20).
“Xerox Holdings Corporation (the “Company”) completed its previously announced private offering of $500 million aggregate principal amount of 8.875% Senior Notes due 2029”
UTHRUNITED THERAPEUTICS Corp
UNITED THERAPEUTICS Corp entered into ASR Agreement with Citibank, N.A. valued at $1.0 billion (effective 2024-03-25).
“On March 25, 2024, the Company entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase approximately $1 billion of the Company’s common stock”
FEFIRSTENERGY CORP
FIRSTENERGY CORP entered into Fourth Amended and Restated Limited Liability Company Agreement of FET with North American Transmission Company II L.P., Brookfield Super-Core Infrastructure Partners L.P., Brookfield Super-Core Infrastructure Partners (NUS) L.P., Brookfield Super-Core Infrastructure Partners (ER) SCSp (effective 2024-03-25).
“On March 25, 2024, pursuant to the terms of the Purchase Agreement and in connection with the Closing, FirstEnergy and FET entered into a Fourth Amended and Restated Limited Liability Company Agreement of FET (the “Fourth LLC Agreement”) with Investor which amends and restates in its entirety the Third Amended and Restated Limited Liability Company Agreement dated as of May 31, 2022”
ORKAOruka Therapeutics, Inc.
Oruka Therapeutics, Inc. amended First Amendment to Office Lease Agreement with Lotus Church Ranch, LLC valued at $8,206.42 (effective 2024-03-19).
“On March 19, 2024, ARCA biopharma, Inc., a Delaware corporation (“ARCA”), entered into the First Amendment to Office Lease Agreement (the “Lease Amendment”) with Lotus Church Ranch, LLC (the “Landlord”), which amended that certain Office Lease Agreement, dated as of August 7, 2020, related to the Company’s headquarters in Westminster, Colorado (the “Lease”). Under the Lease Amendment, the term of the Lease was extended an additional six (6) months through September 30, 2024 (the “Lease Extension”). Commencing on April 1, 2024, the minimum monthly rent shall be increased to $8,206.42.”
MTCHMatch Group, Inc.
Match Group, Inc. amended Ninth Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders party thereto valued at $500 million (effective 2024-03-20).
“Match Group Holdings II, LLC (the “ Company ”), a wholly-owned subsidiary of Match Group, Inc., entered into Amendment No. 9 (the “ Ninth Amendment ”) to that certain amended and restated credit agreement, dated as of October 7, 2015”
ZBRAZEBRA TECHNOLOGIES CORP
ZEBRA TECHNOLOGIES CORP amended Third Amendment with PNC Bank, National Association valued at $180 million (effective 2024-03-19).
“On March 19, 2024, Zebra Technologies International, LLC (“ZTI”) and Zebra Technologies RSC, LLC (“ZTRSC”), both of which are wholly-owned subsidiaries of Zebra Technologies Corporation (the “Company”), entered into the third amendment (the “Third Amendment”) to that certain Receivables Financing Agreement (the “Financing Agreement”), dated as of December 1, 2017, as previously amended on May 20, 2019 and March 19, 2021, by and among ZTI, as originator and servicer, ZTRSC, as borrower, PNC Bank, National Association (“PNC”), as administrative agent, PNC Capital Markets LLC, as structuring agent, and additional persons from time to time party thereto as lenders and group agents (“Lenders”), pursuant to which the Lenders have agreed to provide financing for ZTRSC’s purchase of certain receivables from ZTI.”
HLXHELIX ENERGY SOLUTIONS GROUP INC
HELIX ENERGY SOLUTIONS GROUP INC terminated Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2024-03-20).
“Following the redemption and settlement of the conversions, there were no 2026 Notes outstanding under the Indenture, and the Indenture was satisfied and discharged in accordance with its terms.”
LCTXLineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc. (effective 2024-03-22).
“on March 22, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”), entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”), under which the Company may offer and sell its common shares from time to time through the Sales Agent as the Company’s sales agent.”
APHAMPHENOL CORP /DE/
AMPHENOL CORP /DE/ amended Third Amended and Restated Revolving Credit Agreement with JPMorgan Chase Bank, N.A. valued at $3,000.0 million unsecured revolving commitments maturing March 2029 (effective 2024-03-21).
“On March 21, 2024, Amphenol Corporation (the “ Company ”) entered into a third amended and restated credit agreement among the Company, certain subsidiaries of the Company, as borrowers or as guarantors, a syndicate of financial institutions and JPMorgan Chase Bank, N.A., acting as administrative agent (the “ Revolving Credit Agreement ”).”
SEKISUI HOUSE U.S., INC.
SEKISUI HOUSE U.S., INC. amended Seventh Amendment to Credit Agreement with U.S. Bank National Association, Citibank, N.A., and the other parties that are signatories thereto (effective 2024-03-20).
“Effective March 20, 2024, M.D.C. Holdings, Inc. (the “Company”) entered into a Seventh Amendment to Credit Agreement (“Seventh Amendment”) to its unsecured credit agreement (“Credit Agreement”) with U.S. Bank National Association, as designated agent and co-administrative agent, Citibank, N.A., as co-administrative agent, and the other parties that are signatories thereto.”
NTRPNextTrip, Inc.
NextTrip, Inc. entered into Promissory Note with William Kerby and Donald Monaco, together as holders valued at $500,000 (effective 2024-03-18).
“issued an unsecured line of credit promissory note, in the principal amount of $500,000 (the “Promissory Note”), to William Kerby and Donald Monaco, together as holders”
BCGBinah Capital Group, Inc.
Binah Capital Group, Inc. amended Fifth Amendment to the Credit Agreement with Oak Street Funding LLC.
“Wentworth and certain other borrowers entered into the Fifth Amendment to the Credit Agreement (the “ Amendment ”) with Oak Street”
BCGBinah Capital Group, Inc.
Binah Capital Group, Inc. entered into Voting Agreement with the Holders.
“Pursuant to the terms of the Registration Rights Agreement, the Holders are entitled to certain piggyback registration rights and customary demand registration rights.”
BCGBinah Capital Group, Inc.
Binah Capital Group, Inc. entered into Lock-Up Agreement with the Holders.
“Pursuant to the terms of the Registration Rights Agreement, the Holders are entitled to certain piggyback registration rights and customary demand registration rights.”
BCGBinah Capital Group, Inc.
Binah Capital Group, Inc. entered into Registration Rights Agreement with Pollen Street Capital Limited, Wentworth, certain equity holders of Wentworth and certain other parties.
“the Company entered into that certain Registration Rights Agreement with the PIPE Investor, Wentworth, certain equity holders of Wentworth and certain other parties identified therein (such persons, the “ Holders ”) (the “ Registration Rights Agreement ”)”
BCGBinah Capital Group, Inc.
Binah Capital Group, Inc. entered into Subscription Agreement with Pollen Street Capital Limited valued at aggregate gross proceeds of $14,400,000.
“the Company and Wentworth entered into that certain Subscription Agreement (the “ Subscription Agreement ”) with Pollen Street Capital Limited (the “ PIPE Investor ”), pursuant to which, on the Closing Date, the PIPE Investor subscribed for and purchased, and the Company issued and sold to the PIPE Investor, an aggregate of 1,500,000 Series A Preferred Stock for a purchase price of $9.60 per share, for aggregate gross proceeds of $14,400,000”
Golub Capital Private Credit Fund
Golub Capital Private Credit Fund amended Adviser Revolver Amendment with GC Advisors LLC valued at $200.0 million (effective 2024-03-21).
“On March 21, 2024, Golub Capital Private Credit Fund (“GCRED”) entered into an amendment (the “Adviser Revolver Amendment”) to the unsecured revolving credit agreement, dated as of July 3, 2023 (as amended, the “Adviser Revolver”), by and between GCRED, as the borrower, and GC Advisors LLC, as the lender. The Adviser Revolver Amendment increases the borrowing capacity under the Adviser Revolver from $100.0 million to $200.0 million.”
ShoulderUP Technology Acquisition Corp.
ShoulderUP Technology Acquisition Corp. entered into Business Combination Agreement with SEE ID, Inc. (effective 2024-03-18).
“On March 18, 2024, ShoulderUp Technology Acquisition Corp., a Delaware corporation (“ ShoulderUp ”), entered into a Business Combination Agreement (the “ Business Combination Agreement ”) by and among CID Holdco, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of ShoulderUp (“ Holdings ”), ShoulderUp Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Holdings (“ ShoulderUp Merger Sub ”), SEI Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Holdings (“ SEI Merger Sub ” and together with ShoulderUp Merger Sub, the “ Merger Subs ”), and SEE ID, Inc., a Nevada corporation (collectively with any predecessor entities, the “ Company ”).”
Bannix Acquisition Corp.
Bannix Acquisition Corp. terminated Patent Purchase Agreement with GBT Tokenize Corp. valued at Termination of PPA due to termination of Business Combination Agreement (effective 2024-03-19).
“On March 11, 2024, Bannix sent EVIE and the shareholder of EVIE a notice providing that the Business Combination Agreement has been terminated (“BNIX EVIE Termination Letter”) As the PPA was contingent upon Bannix closing the acquisition of EVIE and due to the BNIX EVIE Termination Letter, on March 19, 2024 Bannix and Tokenize agreed to terminate the PPA which was consented to by GBT.”
Apollo Debt Solutions BDC
Apollo Debt Solutions BDC entered into First Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $650,000,000 6.900% notes due 2029 (effective 2024-03-21).
“On March 21, 2024, Apollo Debt Solutions BDC (the “ Fund ”) and U.S. Bank Trust Company, National Association (the “ Trustee ”) entered into a First Supplemental Indenture (the “ First Supplemental Indenture ” and, together with the Base Indenture (defined herein), the “ Indenture ”) related to the $650,000,000 in aggregate principal amount of its 6.900% notes due 2029 (the “ Notes ”), which supplements that certain Base Indenture, dated as of March 21, 2024 (as may be further amended, supplemented or otherwise modified from time to time, the “ Base Indenture ”).”
MDAISpectral AI, Inc.
Spectral AI, Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD valued at up to $30.0 million (effective 2024-03-20).
“On March 20, 2024, Spectral AI, Inc. (the “ Company ”) entered into the Standby Equity Purchase Agreement (“ SEPA ”) with YA II PN, LTD, a Cayman Islands exempt limited partnership (“ Yorkville ”) pursuant to which the Company has the right to sell to Yorkville up to $30.0 million of its shares of common stock”
SHLSShoals Technologies Group, Inc.
Shoals Technologies Group, Inc. amended Amendment No. 6 to Credit Agreement with JPMorgan Chase Bank, N.A. valued at $200,000,000 new revolving loans; reduces interest rate margin; reduces commitment fee; extends matu (effective 2024-03-19).
“On March 19, 2024 (the "Effective Date"), Shoals Technologies Group, Inc. (the "Company"), as borrower, and certain of its subsidiaries entered into Amendment No. 6 (the "Amendment") to the Credit Agreement, dated as of November 25, 2020, with Wilmington Trust, National Association, as Collateral Agent, JPMorgan Chase Bank, N.A., as Administrative Agent, and each L/C issuer and lender from time to time party thereto (as amended prior to the Effective Date, the "Existing Credit Agreement," and as amended from time to time, the "Amended Credit Agreement").”
PTPIPetros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. amended Omnibus Waiver and Amendment with the Investors (effective 2023-12-31).
“On March 21, 2024, the Company entered into an Omnibus Waiver and Amendment (the “Waiver and Amendment”) with the Investors, effective as of December 31, 2023.”
HOODRobinhood Markets, Inc.
Robinhood Markets, Inc. amended Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. valued at $2.25 billion (effective 2024-03-22).
“On March 22, 2024, Robinhood Securities, LLC (“RHS”), a subsidiary of Robinhood Markets, Inc. (the “Registrant” or “RHM”), entered into the Third Amended and Restated Credit Agreement (the “Credit Agreement”) among RHS, as borrower, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, amending and restating the $2.175 billion 364-day senior secured revolving credit facility entered into in March 2023.”
AIOTPowerfleet, Inc.
Powerfleet, Inc. amended A&R Credit Agreement with Bank Hapoalim B.M. valued at aggregate principal amount of $30 million (effective 2024-03-18).
“On March 18, 2024, Powerfleet Israel Ltd. (“Powerfleet Israel”) and Pointer Telocation Ltd. (“Pointer” and, together with Powerfleet Israel, the “Borrowers”), each a wholly owned subsidiary of PowerFleet, Inc. (the “Company”), entered into an amended and restated credit agreement (the “A&R Credit Agreement”) with Bank Hapoalim B.M. (“Hapoalim”), which refinances the facilities under, and amends and restates, the existing credit agreement, dated August 19, 2019 (as amended, the “Prior Credit Agreement”).”
TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
“In connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.”
TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $1.2 million (effective 2024-03-20).
“On March 20, 2024, TFF Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market (the “Registered Offering”), an aggregate of 147,500 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $8.00 per share (the “Shares”), for gross proceeds from the Registered Offering of approximately $1.2 million, before deducting the placement agent fee and estimated offering expenses.”
ACETAdicet Bio, Inc.
Adicet Bio, Inc. entered into Sales Agreement with Jefferies LLC valued at 3.0% of the gross proceeds (effective 2024-03-22).
“On March 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Open Market Sales Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent or principal.”
Synchrony Card Funding, LLC
Synchrony Card Funding, LLC entered into Class A(2024-1) Terms Document with The Bank of New York Mellon, as Indenture Trustee (effective 2024-03-18).
“On March 18, 2024, Synchrony Card Issuance Trust (the “ Trust ”) and The Bank of New York Mellon, as Indenture Trustee (the “ Indenture Trustee ”), entered into the Class A(2024-1) Terms Document”
SWXSouthwest Gas Holdings, Inc.
Southwest Gas Holdings, Inc. amended Amendment No. 4 with Wells Fargo Bank, National Association (effective 2024-03-22).
“On March 22, 2024, Centuri Group, Inc. (“Centuri”), a wholly owned subsidiary of Southwest Gas Holdings, Inc. (the “Company”), and Centuri Canada Division Inc. entered into Amendment No. 4 (“Amendment No. 4”) to the Second Amended and Restated Credit Agreement”
NTLAIntellia Therapeutics, Inc.
Intellia Therapeutics, Inc. terminated Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, Inc. (effective 2024-03-19).
“On March 19, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) notified Regeneron Pharmaceuticals, Inc. (“Regeneron”) that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement (the “Co-Co Agreement”), which the Company and Regeneron entered into in May 2020.”
XAIRBeyond Air, Inc.
Beyond Air, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd. valued at co-placement agents; 7% cash fee of aggregate gross proceeds (effective 2024-03-20).
“On March 20, 2024, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd. (the “Co-Placement Agents”) as the co-placement agents in connection with the offering.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.